Hallmarks of neurodegenerative diseases
Decades of research have identified genetic factors and biochemical pathways involved in
neurodegenerative diseases (NDDs). We present evidence for the following eight hallmarks …
neurodegenerative diseases (NDDs). We present evidence for the following eight hallmarks …
Blood biomarkers for Alzheimer's disease in clinical practice and trials
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring
Blood biomarkers indicative of Alzheimer's disease (AD) pathology are altered in both
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …
preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for …
Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape
Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration
Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …
Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology
Importance Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …
(AD) pathology, with p-tau217 considered to have the most utility. However, availability of p …
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …
Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications
As the leading cause of dementia, Alzheimer's disease (AD) is a major burden on affected
individuals, their families and caregivers, and healthcare systems. Although AD can be …
individuals, their families and caregivers, and healthcare systems. Although AD can be …
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review
AL Brand, PE Lawler, JG Bollinger, Y Li… - Alzheimer's research & …, 2022 - Springer
The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of
Alzheimer's disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for …
Alzheimer's disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for …
Plasma proteomic profiles predict future dementia in healthy adults
Y Guo, J You, Y Zhang, WS Liu, YY Huang, YR Zhang… - Nature Aging, 2024 - nature.com
The advent of proteomics offers an unprecedented opportunity to predict dementia onset.
We examined this in data from 52,645 adults without dementia in the UK Biobank, with 1,417 …
We examined this in data from 52,645 adults without dementia in the UK Biobank, with 1,417 …